Dr. Clay Siegall is the current president and executive principle of Seattle Genetics. He earned an undergrad in zoology at the renowned University of Maryland and later a Ph.D. in genetics from George Washington University. Dr. Siegall is a scientist with interest in cancer and cancer therapies.
Dr. Siegall role at Seattle Genetics
Dr. Siegall formed Seattle Genetics, a biotechnology and pharmaceutical company, in 1998. In 2000, he took up the role of the president of the company. Two years later, he named the chief executive of the company. Dr. Siegall’s objective was to develop an institute whose mission is to make monoclonal antibody therapies for cancer treatment. It has been roughly 19 years since the creation of Seattle Genetics, and Dr. Siegall takes pride in the success of his company. Under his leadership, Seattle Genetics has become a science-oriented company, conducting rigorous research in the development of therapies for fighting cancer.
Dr. Siegall has facilitated the development of antibody-drug conjugates (ADCs), which are the basis of cancer treatment. Through its ADC technology, Seattle Genetics has entered in strategic licenses with companies such as GlaxoSmithKline, Pfizer, and Genentech. The company has also developed other drugs most of which are still in the clinical trial phase. Seattle has developed ADCETRIS and 33A, which are to be used in the treatment of Hodgkin lymphoma and acute myeloid leukemia respectively. Aside from research work, Dr. Siegall has assisted his company in securing investment capital from various companies amounting to the US $675 million. In 2001, he led the company through an IPO.
Dr. Siegall’s work history
Dr. Siegall’s interest in cancer treatment began close to three decades ago. Before establishing Seattle Genetics, Dr. Siegall worked at National Institute of Health. In 1991, he joined Bristol-Myers Squibb Pharmaceutical Research Institute; a company focused on the development of cost-effective drugs.
Since 2006, Dr. Siegall has been serving on boards of directors for three pharmaceutical companies. He offers advice to the board of directors for Alder Biopharmaceuticals, Inc. as an outside director. In 2013, he was called upon to serve on the board of Mirna Therapeutics, Inc. His recent appointment was at Ultragenyx Pharmaceutical; a biotechnology company committed to the development of drugs for rare and ultra-rare diseases.